InnoCare Pharma and ArriVent Biopharma are joining forces to explore the potential benefits of combining InnoCare’s SHP2 allosteric inhibitor, ICP-189, and ArriVent’s furmonertinib, an EGFR inhibitor that is excellent at penetrating the brain. This ground-breaking clinical development collaboration seeks to assess the efficacy of a dual-drug therapy that may be capable of treating cancer and autoimmune diseases.
InnoCare and ArriVent have reached a landmark agreement to launch a collaborative clinical study, evaluating the anti-tumor activity and safety of the combination of ICP-189 and furmonertinib in patients with advanced non-small cell lung cancer (NSCLC). This groundbreaking research has the potential to significantly improve the treatment outcomes for those suffering from this devastating condition.
ArriVent is leading the charge in a global effort to bring furmonertinib to patients with advanced or metastatic NSCLC associated with EGFR or HER2 mutations, including exon 20 insertion mutations. This innovative drug has already been approved in China as a first-line treatment for adults with locally advanced or metastatic NSCLC with EGFR exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, and thanks to Allist Pharmaceuticals who discovered it, we are now seeing it expand its indications further.
InnoCare’s cutting-edge ICP-189 shows promising potential as a treatment for solid tumors. This potent and selective oral allosteric SHP2 inhibitor has a long half-life and excellent safety and tolerability according to a dose escalation study.
ICP-189 has the additional benefit of being used both as a single agent and in combination with antitumor agents, making this new breakthrough an exciting and potential transformational therapy.
Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, is delighted to collaborate with ArriVent on a combination study to fulfill the unmet medical needs of Non-Small Cell Lung Cancer patients globally. She believes this innovative therapy will give these patients access to beneficial treatment.
We are thrilled to announce this partnership with InnoCare and the advancement of our furmonertinib clinical development program. By combining furmonertinib with ICP-189, we have a tremendous opportunity to potentially provide an additional therapeutic option to those living with advanced or metastatic lung cancer, if approved through successful clinical trials. Our aim is to improve the lives of those affected, and we are confident that this venture can be a success.
NSCLC is the most common form of lung cancer, representing a staggering 85% of cases. This insidious disease is an unfortunate scourge that has impacted countless lives, and yet researchers continue to make progress in battling it.
InnoCare is a forward-thinking biopharmaceutical company on a mission to develop and commercialize groundbreaking drugs for treating cancer and autoimmune diseases with yet-untreated medical needs.
Our comprehensive product portfolio and dedicated staff have earned us recognition for our work in the biopharmaceutical field both in China and worldwide. We have offices in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States, and strive to stay at the cutting-edge of biopharmaceutical innovation.
At ArriVent, we unlock doors to global innovation in biopharma with our deep network and unrivaled access to drug candidates from around the world. By partnering with the world’s leading biotechnology innovators, we are able to bring medicines to patients with unmet medical needs, particularly in oncology. Our mission is to bridge the chasm between great ideas and the opportunity to scale them, and bring life-changing treatments to people in need.